News Focus
News Focus
Replies to #85449 on Biotech Values
icon url

DewDiligence

10/28/09 10:41 PM

#85505 RE: genisi #85449

Late-Stage Products Looking for a Home

Criteria for inclusion:
a) Program is in phase-3 or beyond and is non-partnered; AND
b) Company does not have the financial resources to develop and market the product.

Edits: Removed Cougar’s Abiraterone (co acquired by JNJ); removed
CHTP’s Droxidopa (failed in phase-3); removed DYAX’s DX-88 for HAE
(co plans to market this indication in-house); removed RPRX’s Proellex
(program effectively dead); updated status of SVNT’s Krystexxa, PLX’s
prGCD, and Pharmings’s Rhucin; added MNKD’s Afresa. Changed formatting;
expanded inclusion criteria to programs with inadequate funding for
commercialization (as well as inadequate funding for clinical development).
 
Company Product Phase/status Indication (notes)

======= ======= ============ ==================
ARNA Lorcaserin 3 Obesity
BPAX Libigel 3 Female Sexual Desire Disorder
GNVC TNFerade 3 Non-met pancreatic cancer
JAV Dyloject 3 Post-op pain (approved in UK)
JAV Ketamine 3 Acute pain
OREX Contrave 3 Obesity
OXGN Zybrestat 3 Anaplastic thyroid cancer
MNKD Afresa pre-BLA Type-1/2 diabetes
Pharming Rhucin pre-BLA HAE (rejected and resubmitted in EU)
PLX prGCD pre-BLA Gaucher's disease
SVNT Krystexxa CRL rec’d Gout (CMC section of BLA has problems)

Procedure for Updating Table

1. Copy the text in this post into a word processor.

2. Using a monospace font (e.g. Courier) to facilitate tabular
alignment, make your additions and modifications, inserting
them in the table in alphabetical order. NOTE: use spaces
rather than tab characters.

3. Add a brief note in the “Edits:” line atop the table to
describe your changes.

4. Insert the iHub formatting directives: Put [ pre ] at the
beginning of the table without the surrounding spaces, and
put [ /pre ] at the end of the table without the surrounding
spaces.

5. Post your text as a reply to this message.

Thank you for your cooperation.